The analysis of next-generation sequencing (NGS) data is complex, owing to the breadth of sequences tested and the range of internal biases and errors. In a clinical context, this can lead to false ...

Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows WALTHAM, Mass., June 02, ...

We are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is driving the development of new targeted therapies, coupled with ...

Pharmaceutical impurity reference standards are crucial for ensuring the safety and efficacy of medications. Innovations in this field are driving advancements in life sciences research, offering new ...

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived ...

Usage: Reference standards serve as quality control benchmarks for equipment calibration and verification of measurement methods and analytical accuracy. Characteristics: Chemicals with established ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or ...

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard.

Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows “Accurate diagnosis, including ...